115
Views
5
CrossRef citations to date
0
Altmetric
Theme: Cell and gene therapies - Review

New cell therapies in cardiology

&
Pages 1023-1037 | Published online: 10 Jan 2014

References

  • Henning RJ. Stem cells in cardiac repair. Future Cardiol. 7(1), 99–117 (2011).
  • Alexander JM, Bruneau BG. Lessons for cardiac regeneration and repair through development. Trends Mol. Med. 16(9), 426–434 (2010).
  • Blank AC, van Veen TA, Jonsson MK et al. Rewiring the heart: stem cell therapy to restore normal cardiac excitability and conduction. Curr. Stem Cell Res. Ther. 4(1), 23–33 (2009).
  • Fine GC, Liao R, Sohn RL. Cell therapy for cardiac repair. Panminerva Med. 50(2), 129–137 (2008).
  • Ballard VL. Stem cells for heart failure in the aging heart. Heart Fail. Rev. 15(5), 447–456 (2010).
  • Lee J, Terracciano CM. Cell therapy for cardiac repair. Br. Med. Bull. 94, 65–80 (2010).
  • Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart diseases. Br. Med. Bull. 98, 143–159 (2011).
  • Mummery CL, Davis RP, Krieger JE. Challenges in using stem cells for cardiac repair. Sci. Transl. Med. 2(27), 27ps17 (2010).
  • Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur. Heart J. 32(10), 1197–1206 (2011).
  • Smith RR, Barile L, Messina E, Marbán E. Stem cells in the heart: what’s the buzz all about? – Part 1: preclinical considerations. Heart Rhythm 5(5), 749–757 (2008).
  • Yamahara K, Nagaya N. Stem cell implantation for myocardial disorders. Curr. Drug Deliv. 5(3), 224–229 (2008).
  • Wei HM, Wong P, Hsu LF, Shim W. Human bone marrow-derived adult stem cells for post-myocardial infarction cardiac repair: current status and future directions. Singapore Med. J. 50(10), 935–942 (2009).
  • Joggerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev. Mol. Med. 11, e20 (2009).
  • Gonzales C, Pedrazzini T. Progenitor cell therapy for heart disease. Exp. Cell Res. 315(18), 3077–3085 (2009).
  • Buja LM, Vela D. Current status of the role of stem cells in myocardial biology and repair. Cardiovasc. Pathol. 20(5), 297–301 (2011).
  • Di Nardo P, Forte G, Ahluwalia A, Minieri M. Cardiac progenitor cells: potency and control. J. Cell. Physiol. 224(3), 590–600 (2010).
  • Kearns-Jonker M, Dai W, Kloner RA. Stem cells for the treatment of heart failure. Curr. Opin. Mol. Ther. 12(4), 432–441 (2010).
  • Ke Q, Yang Y, Rana JS, Chen Y, Morgan JP, Xiao YF. Embryonic stem cells cultured in biodegradable scaffold repair infarcted myocardium in mice. Sheng Li Xue Bao 57(6), 673–681 (2005).
  • Singla DK. Embryonic stem cells in cardiac repair and regeneration. Antioxid. Redox Signal. 11(8), 1857–1863 (2009).
  • Tang XL, Rokosh DG, Guo Y, Bolli R. Cardiac progenitor cells and bone marrow-derived very small embryonic-like stem cells for cardiac repair after myocardial infarction. Circ. J. 74(3), 390–404 (2010).
  • Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282(5391), 1145–1147 (1998).
  • Hare JM, Chaparro SV. Cardiac regeneration and stem cell therapy. Curr. Opin. Organ Transplant. 13(5), 536–542 (2008).
  • Asano T, Sasaki K, Kitano Y, Terao K, Hanazono Y. In vivo tumor formation from primate embryonic stem cells. Methods Mol. Biol. 329, 459–467 (2006).
  • Kooreman NG, Wu JC. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J. R. Soc. Interface 7(Suppl. 6), S753–S763 (2010).
  • Cooke MJ, Stojkovic M, Przyborski SA. Growth of teratomas derived from human pluripotent stem cells is influenced by the graft site. Stem Cells Dev. 15(2), 254–259 (2006).
  • Zimmet H, Krum H. Using adult stem cells to treat heart failure – fact or fiction? Heart. Lung Circ. 17(Suppl. 4), S48–S54 (2008).
  • Hentze H, Graichen R, Colman A. Cell therapy and the safety of embryonic stem cell-derived grafts. Trends Biotechnol. 25(1), 24–32 (2007).
  • Kajstura J, Urbanek K, Perl S et al. Cardiomyogenesis in the adult human heart. Circ. Res. 107(2), 305–315 (2010).
  • Beitnes JO, Lunde K, Brinchmann JE, Aakhus S. Stem cells for cardiac repair in acute myocardial infarction. Expert Rev. Cardiovasc. Ther. 9(8), 1015–1025 (2011).
  • Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 327(5965), 542–545 (2010).
  • Strauer BE, Brehm M, Schannwell CM. The therapeutic potential of stem cells in heart disease. Cell Prolif. 41(Suppl. 1), 126–145 (2008).
  • Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Bone marrow stem cells regenerate infarcted myocardium. Pediatr. Transplant. 7(Suppl. 3), 86–88 (2003).
  • Quyyumi AA, Murrow J. Stem cells in cardiovascular disease. Med. Arh. 64(5), 289–294 (2010).
  • Rameshwar P, Qiu H, Vatner SF. Stem cells in cardiac repair in an inflammatory microenvironment. Minerva Cardioangiol. 58(1), 127–146 (2010).
  • Rangappa S, Makkar R, Forrester J. Review article: current status of myocardial regeneration: new cell sources and new strategies. J. Cardiovasc. Pharmacol. Ther. 15(4), 338–343 (2010).
  • Siu CW, Liao SY, Liu Y, Lian Q, Tse HF. Stem cells for myocardial repair. Thromb. Haemost. 104(1), 6–12 (2010).
  • Shah VK, Shali KK. Regeneration of myocardium – dawn of a new era! J. Assoc. Physicians India 57, 312–324, 329 (2009).
  • Kajstura J, Urbanek K, Rota M et al. Cardiac stem cells and myocardial disease. J. Mol. Cell. Cardiol. 45(4), 505–513 (2008).
  • Dawn B, Zuba-Surma EK, Abdel-Latif A, Tiwari S, Bolli R. Cardiac stem cell therapy for myocardial regeneration. A clinical perspective. Minerva Cardioangiol. 53(6), 549–564 (2005).
  • Bearzi C, Rota M, Hosoda T et al. Human cardiac stem cells. Proc. Natl Acad. Sci. USA 104(35), 14068–14073 (2007).
  • Palpant NJ, Metzger JM. Aesthetic cardiology: adipose-derived stem cells for myocardial repair. Curr. Stem Cell Res. Ther. 5(2), 145–152 (2010).
  • Menasché P, Hagège AA, Scorsin M et al. Myoblast transplantation for heart failure. Lancet 357(9252), 279–280 (2001).
  • Pagani FD, Der Simonian H, Zawadzka A et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J. Am. Coll. Cardiol. 41(5), 879–888 (2003).
  • Codina M, Elser J, Margulies KB. Current status of stem cell therapy in heart failure. Curr. Cardiol. Rep. 12(3), 199–208 (2010).
  • Shiba Y, Hauch KD, Laflamme MA. Cardiac applications for human pluripotent stem cells. Curr. Pharm. Des. 15(24), 2791–2806 (2009).
  • Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6), 763–776 (2003).
  • Galiñanes M, Loubani M, Davies J, Chin D, Pasi J, Bell PR. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant. 13(1), 7–13 (2004).
  • Sussman MA, Murry CE. Bones of contention: marrow-derived cells in myocardial regeneration. J. Mol. Cell. Cardiol. 44(6), 950–953 (2008).
  • Olivares EL, Ribeiro VP, Werneck de Castro JP et al. Bone marrow stromal cells improve cardiac performance in healed infarcted rat hearts. Am. J. Physiol. Heart Circ. Physiol. 287(2), H464–H470 (2004).
  • Chugh AR, Zuba-Surma EK, Dawn B. Bone marrow-derived mesenchymal stems cells and cardiac repair. Minerva Cardioangiol. 57(2), 185–202 (2009).
  • Makino S, Fukuda K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 103(5), 697–705 (1999).
  • Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ. Res. 109(8), 923–940 (2011).
  • van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P et al. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc. Res. 91(4), 649–658 (2011).
  • Nagaya N, Kangawa K, Itoh T et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112(8), 1128–1135 (2005).
  • Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428(6983), 664–668 (2004).
  • Davis DR, Stewart DJ. Autologous cell therapy for cardiac repair. Expert Opin. Biol. Ther. 11(4), 489–508 (2011).
  • Schächinger V, Erbs S, Elsässer A et al. REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1210–1221 (2006).
  • Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364(9429), 141–148 (2004).
  • Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367(9505), 113–121 (2006).
  • Kofidis T, de Bruin JL, Yamane T et al. Insulin-like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. Stem Cells 22(7), 1239–1245 (2004).
  • Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat. Cell Biol. 13(5), 497–505 (2011).
  • Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 324(5923), 98–102 (2009).
  • Müller-Ehmsen J, Whittaker P, Kloner RA et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J. Mol. Cell. Cardiol. 34(2), 107–116 (2002).
  • Smits AM, van Laake LW, den Ouden K et al. Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovasc. Res. 83(3), 527–535 (2009).
  • Gluckman E. Ten years of cord blood transplantation: from bench to bedside. Br. J. Haematol. 147(2), 192–199 (2009).
  • Henning RJ, Burgos JD, Vasko M et al. Human cord blood cells and myocardial infarction: effect of dose and route of administration on infarct size. Cell Transplant. 16(9), 907–917 (2007).
  • Kränkel N, Spinetti G, Amadesi S, Madeddu P. Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol. Ther. 129(1), 62–81 (2011).
  • Limana F, Capogrossi MC, Germani A. The epicardium in cardiac repair: from the stem cell view. Pharmacol. Ther. 129(1), 82–96 (2011).
  • Brunner S, Engelmann MG, Franz WM. Stem cell mobilisation for myocardial repair. Expert Opin. Biol. Ther. 8(11), 1675–1690 (2008).
  • Post S, Goumans MJ, Doevendans PA. Peripheral blood derived cell trafficking for cardiac regeneration. Curr. Stem Cell Res. Ther. 5(4), 303–313 (2010).
  • Madonna R, De Caterina R. Stem cells and growth factor delivery systems for cardiovascular disease. J. Biotechnol. 154(4), 291–297 (2011).
  • Kolettis TM, Vilaeti A, Dimos K, Tsitou N, Agathopoulos S. Tissue engineering for post-myocardial infarction ventricular remodeling. Mini Rev. Med. Chem. 11(3), 263–270 (2011).
  • Voog J, Jones DL. Stem cells and the niche: a dynamic duo. Cell Stem Cell 6(2), 103–115 (2010).
  • Stastna M, Abraham MR, Van Eyk JE. Cardiac stem/progenitor cells, secreted proteins, and proteomics. FEBS Lett. 583(11), 1800–1807 (2009).
  • Askari AT, Unzek S, Popovic ZB et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362(9385), 697–703 (2003).
  • Kavanagh DP, Kalia N. Hematopoietic stem cell homing to injured tissues. Stem Cell Rev. 7(3), 672–682 (2011).
  • Tang YL, Zhu W, Cheng M et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ. Res. 104(10), 1209–1216 (2009).
  • Ferrari R, Beltrami CA, Tavazzi L. Concerns and hopes for stem cell therapy in cardiology: focus on endothelial progenitor cells. Cardiovasc. Hematol. Disord. Drug Targets 10(3), 216–223 (2010).
  • Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1199–1209 (2006).
  • Fischer-Rasokat U, Assmus B, Seeger FH et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circ. Heart Fail. 2(5), 417–423 (2009).
  • Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat. Rev. Cardiol. 7(4), 204–215 (2010).
  • Krause K, Schneider C, Kuck KH, Jaquet K. Stem cell therapy in cardiovascular disorders. Cardiovasc. Ther. 28(5), e101–e110 (2010).
  • Van Oorschot AA, Smits AM, Goumans MJ. Stem cells: the building blocks to repair the injured heart. Panminerva Med. 52(2), 97–110 (2010).
  • Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail. Rev. 16(1), 13–21 (2011).
  • Bartunek J, Vanderheyden M, Hill J, Terzic A. Cells as biologics for cardiac repair in ischaemic heart failure. Heart 96(10), 792–800 (2010).
  • Ieda M, Fu JD, Delgado-Olguin P et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142(3), 375–386 (2010).
  • Fischer KM, Cottage CT, Wu W et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 120(21), 2077–2087 (2009).
  • Rota M, Boni A, Urbanek K et al. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ. Res. 97(12), 1332–1341 (2005).
  • Behfar A, Zingman LV, Hodgson DM et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J. 16(12), 1558–1566 (2002).
  • Ang KL, Chin D, Leyva F et al. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat. Clin. Pract. Cardiovasc. Med. 5(10), 663–670 (2008).
  • Mathiasen AB, Haack-Sørensen M, Kastrup J. Mesenchymal stromal cells for cardiovascular repair: current status and future challenges. Future Cardiol. 5(6), 605–617 (2009).
  • Paul D, Samuel SM, Maulik N. Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid. Redox Signal. 11(8), 1841–1855 (2009).
  • Huikuri HV, Kervinen K, Niemelä M et al. FINCELL Investigators. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur. Heart J. 29(22), 2723–2732 (2008).
  • Psaltis PJ, Zannettino AC, Gronthos S, Worthley SG. Intramyocardial navigation and mapping for stem cell delivery. J. Cardiovasc. Transl. Res. 3(2), 135–146 (2010).
  • Stamm C, Kleine HD, Choi YH et al. Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J. Thorac. Cardiovasc. Surg. 133(3), 717–725 (2007).
  • van Vliet P, Roccio M, Smits AM et al. Progenitor cells isolated from the human heart: a potential cell source for regenerative therapy. Neth. Heart J. 16(5), 163–169 (2008).
  • Klopsch C, Furlani D, Gäbel R et al. Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J. Cell. Mol. Med. 13(4), 664–679 (2009).
  • Assmus B, Schächinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106(24), 3009–3017 (2002).
  • Dib N, Dinsmore J, Lababidi Z et al. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc. Interv. 2(1), 9–16 (2009).
  • ter Horst KW. Stem cell therapy for myocardial infarction: are we missing time? Cardiology 117(1), 1–10 (2010).
  • Dai W, Hale SL, Martin BJ et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 112(2), 214–223 (2005).
  • Yeo C, Mathur A. Autologous bone marrow-derived stem cells for ischemic heart failure: REGENERATE-IHD trial. Regen. Med. 4(1), 119–127 (2009).
  • Dib N, Michler RE, Pagani FD et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 112(12), 1748–1755 (2005).
  • Strauer BE, Yousef M, Schannwell CM. The Acute and Long-Term Effects of Intracoronary Stem cell Transplantation in 191 Patients with Chronic Heart Failure: the STAR-Heart study. Eur. J. Heart Fail. 12(7), 721–729 (2010).
  • Seth S, Narang R, Bhargava B et al. AIIMS Cardiovascular Stem Cell Study Group. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J. Am. Coll. Cardiol. 48(11), 2350–2351 (2006).
  • Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 26(9), 2201–2210 (2008).
  • Wojakowski W, Tendera M. New concepts in cardiac stem cell therapy. Hellenic J. Cardiol. 51(1), 10–14 (2010).
  • Gaetani R, Barile L, Forte E et al. New perspectives to repair a broken heart. Cardiovasc. Hematol. Agents Med. Chem. 7(2), 91–107 (2009).
  • Gersh BJ, Simari RD, Behfar A, Terzic CM, Terzic A. Cardiac cell repair therapy: a clinical perspective. Mayo Clin. Proc. 84(10), 876–892 (2009).
  • Janssens S. Stem cells in the treatment of heart disease. Annu. Rev. Med. 61, 287–300 (2010).
  • Lovell MJ, Mathur A. Cardiac stem cell therapy: progress from the bench to bedside. Heart 96(19), 1531–1537 (2010).
  • Xing YJ, Lü AL, Zhao XM, Li F, Wang L, DU JJ. Current state of myocardial tissue engineering. Chin. Med. J. 122(15), 1811–1815 (2009).
  • Lovell MJ, Mathur A. Republished review: Cardiac stem cell therapy: progress from the bench to bedside. Postgrad. Med. J. 87(1030), 558–564 (2011).
  • Beeres SL, Atsma DE, van Ramshorst J, Schalij MJ, Bax JJ. Cell therapy for ischaemic heart disease. Heart 94(9), 1214–1226 (2008).
  • Yang YJ, Qian HY, Huang J et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur. Heart J. 29(12), 1578–1590 (2008).
  • Fujii H, Li SH, Wu J et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur. Heart J. 32(16), 2075–2084 (2011).
  • Hirsch A, Nijveldt R, van der Vleuten PA et al. HEBE Investigators. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur. Heart J. 32(14), 1736–1747 (2011).
  • Theiss HD, Brenner C, Engelmann MG et al. Safety and Efficacy of Sitagliptin Plus Granulocyte-Colony-Stimulating Factor in Patients Suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) – rationale, design and first interim analysis. Int. J. Cardiol. 145(2), 282–284 (2010).
  • Tendera M, Wojakowski W, Ruzyllo W et al. REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur. Heart J. 30(11), 1313–1321 (2009).
  • Gyöngyösi M, Lang I, Dettke M et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat. Clin. Pract. Cardiovasc. Med. 6(1), 70–81 (2009).
  • Menasché P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117(9), 1189–1200 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.